This challenge targets the hypothesis: **APOE4-Specific Proteolytic Fragment Inhibition Therapy** **Hypothesis Summary:** ## Mechanistic Overview APOE4-Specific Proteolytic Fragment Inhibition Therapy starts from the claim that modulating APOE within the disease context of Alzheimer's disease can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The pathophysiology of APOE4-related neurodegeneration centers on the structural vulnerability of the APOE4 isoform to aberrant proteolytic processing, which generates highly neurotoxic C-terminal fragments. Unlike A **Falsifiable Predictions:** 1. Pharmacological modulation of APOE will alter Alzheimer's disease markers in validated models by ≥20% 2. Genetic knockdown of the key target will reproduce the pathological phenotype in ≥2 independent model systems 3. Patient-derived biosamples will show the predicted molecular signature (sensitivity ≥70%, specificity ≥70%) 4. Mechanistic intervention at the proposed node will rescue neuronal viability in vitro by ≥30% **Bounty Tier:** $127,700 USD (composite score 0.777) **Challenge Type:** Open — any team may submit experimental evidence supporting or refuting this hypothesis **Success Criteria:** Peer-reviewed evidence demonstrating mechanistic validation of ≥2 of the 4 predictions, with independent replication.